Cantor Fitzgerald and Leerink Partners initiated analyst coverage on Avidity Biosciences on August 10, 2026.

The entities involved

• Avidity →

  American biotech company

  • Novartis acquired Avidity in a $12 billion purchase, while Trump simultaneously threatened Swiss businesses with tariffs.Sat 01:46
• Cantor Fitzgerald →

  American financial services company

  • SoundHound is listed on the Nasdaq stock exchange, and its CEO has outlined the company's acquisition strategy.Mon 04:01
  • Analyst firm lowered price targets on Automatic Data Processing (ADP) stock on June 6, 2026.Sun 18:41
• Leerink partners →

  U.S. investment bank

  • Analyst firm set price targets for Leerink partners' client, Twist Bioscience, on June 26, 2026. Concurrently, the CEO sold shares due to tax withholding obligations.Mon 08:52
  • A filing required by the SEC concerning McKesson Corporation shares, accompanied by analyst commentary.Sun 22:38

Related events

• Cantor Fitzgerald hosted a healthcare conference on September 8, 2026.Sep 8
• Avidity Biosciences, a San Diego-based company, announced a partnership with Eli Lilly and is also facing acquisition interest from Novartis.Jun 7
• Cantor Fitzgerald began coverage and issued rating, and Morgan Stanley upgraded price objective and rating for Silence Therapeutics.Wed 20:36